Introduction: Although there are several ways to relief pain in metastatic patients, the use of radionuclides is one of the known and effective ways to relieve the pain caused by bone metastases. The purpose of this study was to assessment of radiation dose distribution of different radioisotopes used to treatment and pain relief patients in a bone-based model based on Monte C...

Objective(s): Recently, bone-avid radiopharmaceuticals have been shown to have potential benefits for the treatment of widespread bone metastases. Although 177Lutriethylene tetramine hexa methylene phosphonic acid (abbreviated as 177Lu- TTHMP), as an agent for bone pain palliation, has been evaluated in previous studies, there are large discrepancies between the obtained results. In this study,...

objective(s): recently, bone-avid radiopharmaceuticals have been shown to have potential benefits for the treatment of widespread bone metastases. although 177lutriethylene tetramine hexa methylene phosphonic acid (abbreviated as 177lu- tthmp), as an agent for bone pain palliation, has been evaluated in previous studies, there are large discrepancies between the obtained results. in this study,...

Introduction: There are many ways to treat cancer and pain relief. One of the methods is radiopharmaceutical therapy. Indium 111-rituximab contains the radioisotope indium-111 and rituximab. The Indium-111, after decay, emits gamma rays with energies of 245 KeV and 171 KeV, and beta-radiation of 26 KeV. In this study, the absorbed dose of 111In-Rituximab in human body was calcu...

PURPOSE Rats have been widely used in radionuclide therapy research for the treatment of hepatocellular carcinoma (HCC). This has created the need to assess rat liver absorbed radiation dose. In most dose estimation studies, the rat liver is considered as a homogeneous integrated target organ with a tissue composition assumed to be similar to that of human liver tissue. However, the rat liver i...

introduction: using beta emitter radionuclide is a useful therapeutic modality in the treatment of skin cancers in areas which are difficult to cure by other methods. the aim of this research is to evaluate the tissue response to beta rays of 166ho and determine the feasibility of beta emitting radionuclide for treatment of skin cancers. methods: in this work, we have calculated depth dose dist...

Radionuclide therapy is widely used as an effective modality in the management of bone pain. The main indication for this treatment is symptomatic bone metastases, confirmed by bone scintigraphy. We present a case of small cell lung cancer (SCLC) stage T4N2M1b, with a good metabolic response to systemic therapy and radiotherapy of the primary tumor and locoregional disease, which became metabol...

BACKGROUND Somatostatin analogue-based radionuclide therapy with (177)Lu-DOTATATE is an important treatment option for patients with advanced neuroendocrine tumours overexpressing somatostatin receptors. In addition to the kidneys, the bone marrow is a major dose-limiting organ. The correlation between developed haematological toxicity and absorbed dose to the bone marrow is poor, which indicat...

  Introduction: Using beta emitter radionuclide is a useful therapeutic modality in the treatment of skin cancers in areas which are difficult to cure by other methods. The aim of this research is to evaluate the tissue response to beta rays of 166Ho and determine the feasibility of beta emitting radionuclide for treatment of skin cancers. Methods: In this...

Radionuclide therapy extends the usefulness of radiation from localized disease of multifocal disease by combining radionuclides with disease-seeking drugs, such as antibodies or custom-designed synthetic agents. Like conventional radiotherapy, the effectiveness of targeted radionuclides is ultimately limited by the amount of undesired radiation given to a critical, dose-limiting normal tissue,...